Market Place
Sourcing Support
All News #Library
Biotech
CEL-SCI to Partner Saudi Pharma for Multikine in Head & Neck
11 Jul 2025 //
BUSINESSWIRE
CEL-SCI Prices $5.7 Million Offering At Market Under NYSE Rules
11 Jul 2025 //
BUSINESSWIRE
Keytruda Nod Highlights CEL-SCI Opportunity in PD-L1– Cancers
18 Jun 2025 //
BUSINESSWIRE
CEL-SCI to Seek Regulatory Approval for Multikine in Saudi Arabia
23 Apr 2025 //
BUSINESSWIRE
Cel-Sci Eyes Early Multikine Approval in Head, Neck Cancer
08 Apr 2025 //
BUSINESSWIRE
JAMA Study: CEL-SCI`s Multikine Treats 70% Head, Neck Patients
14 Mar 2025 //
BUSINESSWIRE
FDA & CEL-SCI Agree on PD-L1 Biomarker for Head & Neck Cancer Study
07 Nov 2024 //
BUSINESSWIRE
CEL-SCI To Present Multikine® Data At ESMO 2024 Congress
10 Sep 2024 //
BUSINESSWIRE
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Rheumatoid Arthritis
19 Mar 2024 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.